Found: 5
Select item for more details and to access through your institution.
Sequential therapy of refractory metastatic pancreatic cancer with 5-FU/LV/irinotecan (FOLFIRI) vs. 5-FU/LV/oxaliplatin (OFF). The PANTHEON trial (AIO PAK 0116).
- Published in:
- Journal of Cancer Research & Clinical Oncology, 2024, v. 150, n. 7, p. 1, doi. 10.1007/s00432-024-05827-x
- By:
- Publication type:
- Article
Highlights of Translational and Molecular Research Presented at the European Society for Medical Oncology Annual Meeting 2023.
- Published in:
- Oncology Research & Treatment, 2024, v. 47, n. 4, p. 149, doi. 10.1159/000537940
- By:
- Publication type:
- Article
Follow-up lung ultrasound to monitor lung failure in COVID-19 ICU patients.
- Published in:
- PLoS ONE, 2022, v. 17, n. 7, p. 1, doi. 10.1371/journal.pone.0271411
- By:
- Publication type:
- Article
Response and Disease Dynamics in Untreated Metastatic Colorectal Cancer With Bevacizumab-Based Sequential vs. Combination Chemotherapy—Analysis of the Phase 3 XELAVIRI Trial.
- Published in:
- Frontiers in Oncology, 2022, v. 12, p. 1, doi. 10.3389/fonc.2022.751453
- By:
- Publication type:
- Article
Mutational profiles of metastatic colorectal cancer treated with FOLFIRI plus cetuximab or bevacizumab before and after secondary resection (AIO KRK 0306; FIRE‐3).
- Published in:
- International Journal of Cancer, 2021, v. 149, n. 11, p. 1935, doi. 10.1002/ijc.33747
- By:
- Publication type:
- Article